Form 4: AEON Biopharma Director Shelley B. Thunen Acquires Stock Options

Director Shelley B. Thunen acquired 16,260 stock options in AEON Biopharma, Inc. on March 19, 2024.

Summary

• Shelley B. Thunen, a director of AEON Biopharma, Inc., acquired 16,260 stock options on March 19, 2024.
• The options have an exercise price of $14.40.
• The options vest in equal monthly installments over one year from the grant date, subject to continued service.
• Full vesting occurs upon a Change in Control of the Company.
• Following the transaction, Thunen directly owns 16,260 derivative securities.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard disclosure of stock option grants to a director. While insider ownership can be a positive signal, this is a routine grant.

Positives

• The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company insiders.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment if viewed as a sign of confidence by a company director.

Key Dates

Keywords

stock options, director, AEON Biopharma, acquisition, Form 4, insider trading